Research and Markets: Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control Issues

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d141a8/strategies_for_man) has announced the addition of the "Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control Issues" report to their offering.

“Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control Issues”

In 2007, due to the impending patent cliff and the consequent need to cut costs, big pharma began for the first time to outsource chemical API manufacturing to China and India. Prior to this only generic drug companies had manufactured in the two countries. Since then, big pharma has been undergoing waves of layoffs that have been accelerated by the economic downturn, with manufacturing and sales being particularly affected, and outsourcing levels in R&D and manufacturing are expected to increase further in the future.

This report examines the different strategies available for managing the layoffs and site closures resulting from not only the outsourcing of R&D and manufacturing, but also the transition from small-molecules to biologics and the need to exploit new markets. The factors causing change and producing the need for workforce reductions are analysed, and the expected impact across the pharmaceutical workforce in the US is detailed. The consequences of layoffs and site closures in terms of legal compliance, maintenance of productivity, and safeguarding of quality control are discussed in depth. Case studies from the pharmaceutical industry are provided to highlight pitfalls and illustrate best practice. The report concludes with discussion of the long-term risks associated with over-dependence on expansion in nonmarket economies and suggests methods to lower these risks.

Key findings from this report

• The projected growth from 2008-2018 for US pharmaceutical and medicine manufacturing employment lags behind the projected employment growth for all US industries, at 6% versus 11% respectively, due to generic competition and drug production moving overseas.
• OECD synthetic indicators measure the strictness of overall employment protection against dismissals of part- and full-time employees and restrictions on temporary hires, and are low for the US, Canada, and the UK; intermediate for Ireland, Japan, and Hungary; and high for Germany, China, India, and France.
• Companies that work closely with regional stakeholders will gain partners who assist with marketing and locating financial investment and potential buyers for the closed facility.
• The timing of workforce reduction announcements can be crucial to the reception both within the workforce and in the wider community. In some cases, poorly chosen timing has significantly complicated the layoff process and has generated considerable bad press.

Key Topics Covered:

• Chapter 1 Introduction
• Chapter 2 Pharmaceutical employment trends in developed nations
• Chapter 3 Legal regulations and considerations
• Chapter 4 Managing employees through workforce reductions
• Chapter 5 Biotech and pharma workforce reductions
• Chapter 6 R&D and manufacturing site closures
• Chapter 7 Outsourcing and off shoring for research and manufacturing
• Chapter 8 Long-term risks of off shoring
• List of Figures
• List of Tables

Companies Mentioned:

• Case studies:
• Sanofi-Aventis
• J&Js McNeil Consumer Healthcare
• Eli Lilly with Evonik
• Pfizer
• Teva

For more information visit http://www.researchandmarkets.com/research/d141a8/strategies_for_man

Source: Business Insights